Natural products in anticancer therapy

Current Opinion in Pharmacology

Volumn 1, Issue 4, 2001, Pages 364-369

  Da Rocha, Adriana B ^a   Lopes, Rafael M ^a   Schwartsmann, Gilberto ^a  

^a UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

Author keywords

Anti cancer drugs; Cancer Biology; Drug Discovery; Natural compounds; Pharmacology

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT; MARINE TOXIN;

ANIMAL; BACTERIUM; CHEMISTRY; FUNGUS; HUMAN; NEOPLASM; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BACTERIA; BIOLOGICAL PRODUCTS; FUNGI; HUMANS; MARINE TOXINS; NEOPLASMS;

EID: 0035433799     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(01)00063-7     Document Type: Review

References (67)

1. Farnsworth N.R., Akerele O., Bingel A.S., Soejarto D.D., Guo Z. Medicinal plants in therapy. Bull World Health Organ. 63:1985;965-981.
2. Cragg G.M., Newman D.J., Snader K.M. Natural products in drug discovery and development. J Nat Prod. 60:1997;52-60.
3. Balandrin M.F., Kinghorn A.D., Farnsworth N.R. Plant-derived natural products in drug discovery and development: an overview. Kinghorn A.D., Balandrin M.F. Human Medicinal Agents from Plants. 1993;2-12 Oxford University Press USA, North Carolina, USA. [American Chemical Society Symposium Series.].
4. Farnsworth N.R. The role of ethnopharmacology in drug development. Ciba Found Symp. 154:1990;2-11.
5. Cragg G.M., Newman D.J. Discovery and development of antineoplastic agents from natural sources. Cancer Invest. 17:1999;153-163.
6. Wani M.C., Taylor H.L., Wall M.E., Coggon P., McPhail A.T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 93:1971;2325-2327.
7. Cortes J.E., Pazdur R. Docetaxel. J Clin Oncol. 13:1995;2643-2655.
8. Schwartsmann G. Marine organisms and other novel natural sources of new anticancer drugs. Ann Oncol. 11:2000;235-243.
9. Schwartsmann G., Rocha A.B., Berlinck R., Jimeno J. Marine organisms as a source of new anticancer agents. Lancet Oncol. 2:2001;221-225.
10. Mans D.R.A., Rocha A.B., Schwartsmann G. Anti-cancer drug discovery and development in Brazil: targeted plant collection as a rational strategy to acquire candidate anti-cancer compounds. Oncologist. 5:2000;185-199.
11. Noble R.L. The discovery of the vinca alkaloids - chemotherapeutic agents against cancer. Biochem Cell Biol. 68:1990;1344-1351.
12. DeVita V.T. Jr, Serpick A.A., Carbone P.O. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 73:1970;881-895.
13. Williams S.D., Birch R., Einhorn L.H., Irwin L., Greco F.A., Loehrer P.J. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. New Engl J Med. 316:1987;1435-1440.
14. Stähelin H. Actvity of a new glycosidic lignan derivative (VP-16-213) related to podophyllotoxin in experimental tumors. Eur J Cancer. 9:1973;215-221.
15. Chabner B.A. Anticancer drugs. DeVita V.T. Jr, Hellman S., Rosenberg A.S. Cancer: Principles and Practice. 4 :1991;325-417 Lippincott, Philadelphia.
16. Perry M.C. Perry M.C. The chemotherapy sourcebook. 1992;Williams & Wilkins, Baltimore.
17. Harvey A.L. Medicines from nature: are natural products still relevant to drug discovery? Trends Pharmacol Sci. 20:1999;196-198.
18. Liu L.F. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem. 58:1989;351-375.
19. Creemers G.J., Bolis G., Gore M., Scarfone G., Lacave A.J., Guastalla J.P., Despax R., Favalli G., Kreinberg R., Van Belle S., et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer. J Clin Oncol. 14:1996;3056-3061.
20. Bertino J.R. Irinotecan for colorectal cancer. Semin Oncol. 24:1997;S18-S23.
21. Liu L.F., Desai S.D., Li T.K., Mao Y., Sun M., Sim S.P. Mechanism of action of camptothecin. Ann New York Acad Sci. 922:2000;1-10.
22. Kelland L.R. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Expert Opin Invest Drugs. 9:2000;2903-2911. This review focuses on the clinical development of flavopiridol, the prototype broad-spectrum inhibitor of cyclin-dependent kinases.
23. Harmon A.D., Weiss U., Silverton J.V. The structure of rohutukine, the main alkaloid of Amoora rohituka (syn. Aphanamixis polystachya) (Maliaceae). Tetrahydron. 20:1979;721-724.
24. Cragg G., Suffness M. Metabolism of plant-derived anticancer agents. Pharmacol Ther. 37:1988;425-432.
25. Worland P.J., Kaur G., Stetler-Stevenson M., Sebers S., Sartor O., Sausville E.A. Alteration of the phosphorylation state of p32cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Biochem Pharmacol. 46:1993;1831-1836.
26. Losiewicz M.D., Carlson B.A., Kaur G., Sausville E.A., Worland P.J. Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun. 201:1994;589-595.
27. Senderowicz A.M., Headlee D., Stinson S.F., Lush R.M., Kalil N., Villalba L., Hill K., Steinberg S.M., Figg W.D., Tompkins A., et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol. 16:1998;2986-2999.
28. Wright J., Blatner G.L., Cheson B.D. Clinical trials referral resource. Clinical trials of flavopiridol. Oncology. 12:1998;1023-1024.
29. Kaur G., Stetler-Stevenson M., Sebers S., Worland P., Sedlacek H., Myers C., Czech J., Naik R., Sausville E. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst. 84:1992;1736-1740.
30. Powell R.G., Weisleder D., Smith C.R. Jr, Rohwedder W.K. Structures of harringtonine, isoharringtonine, and homoharringtonine. Tetrahydron Lett. 11:1970;815-818.
31. Kantarjian H.M., O'Brien S., Anderlini P., Talpaz M. Treatment of myelogenous leukemia: current status and investigational options. Blood. 87:1996;3069-3081.
32. Zhou D.C., Zittoun R., Marie J.P. Homoharringtonine: an effective new natural product in cancer chemotherapy. Bull Cancer. 82:1995;987-995.
33. Rehm S., Devor D.E. Acute effects of 4-ipomeanol on experimental lung tumors with bronchiolar or alveolar cell features in Syrian hamsters or C3H/HeNCr mice. J Cancer Res Clin Oncol. 120:1993;41-50.
34. Rowinsky E.K., Noe D.A., Ettinger D.S., Christian M.C., Lubejko B.G., Fishman E.K., Sartorius S.E., Boyd M.R., Donehower R.C. Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans. Cancer Res. 53:1993;1794-1801.
35. Li Y.Z., Li C.J., Pinto A.V., Pardee A.B. Release of mitochondrial cytochrome c in both apoptosis and necrosis induced by β-lapachone in human carcinoma cells. Mol Med. 4:1999;232-239.
36. Cragg G.M., Newman D.J., Weiss R.B. Coral reefs, forests, and thermal vents: the worldwide exploration of nature for novel antitumor agents. Semin Oncol. 24:1997;156-163.
37. Binaschi M., Farinosi R., Borgnetto M.E., Capranico G. In vivo site specificity and human isoenzyme selectivity of two topoisomerase II poisoning anthracyclines. Cancer Res. 60:2000;3770-3776.
38. Patrick Y. Major microbial diversity initiative recommended. AmSoc Microbiol News. 63:1997;417-421.
39. Alberts M.W., Williams R.T., Brown E.J., Tanaka A., Hall F.L., Schreiber S.L. FKBP-Rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early Gl of an osteosarcoma cell line. J Biol Chem. 268:1993;22825-22829.
40. Schulte T.W., Neckers L.M. The benzoquinone ansamycin 17-allylamino-17demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol. 42:1998;273-279.
41. Cadenas M.E., Sandfrison A., Cutler N.S., Heitman J. Signal-transduction cascades as targets for therapeutic intervention by natural products. Trends Biotechnol. 16:1998;427-433.
42. Adjei A.A. Signal transduction pathway targets for anticancer drug discovery. Curr Pharmaceut Design. 6:2000;361-378. This article provides an excellent overview of the anticancer agents inhibiting signal transduction pathway molecules that have entered clinical trials.
43. Pomponi A.S. The bioprocess-technological potential of the sea. J Biotechnol. 70:1999;5-13.
44. Schweitzer J., Handley F.G., Edwards J., Harris W.F., Grever M.R., Schepartz S.A., Cragg G., Snader K., Bhat A. Summary of the workshop on drug development, biological diversity, and workshop on drug development, biological diversity, and economic growth. J Natl Cancer Inst. 83:1991;1294-1298.
45. Rinehart K.L. Antitumor compounds from tunicates. Med Res Rev. 20:2000;1-27.
46. Chun H.G., Davies B., Hoth D., Suffness M., Plowman J., Flora K., Grieshaber C., Leyland-Jones B., Didemnin B. The first marine compound entering clinical trials as an antineoplastic agent. Invest New Drugs. 4:1986;279-284.
47. Shin D.M., Holoye P.Y., Murphy W.K., Forman A., Papasozomenos S.C., Hong W.K., Raber M. Phase I/II clinical trial of didemnin B in non-small cell lung cancer: neuromuscular toxicity is dose-limiting. Cancer Chemother Pharmacol. 29:1991;145-149.
48. Urdiales J.L., Morata P., Nunez de Castro I., Sanchez-Jimenez F. Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates. Cancer Lett. 102:1996;31-37.
49. Geldof A.A., Mastbergen S.C., Henrar R.E.C., Faircloth G.T. Cytotoxicity and neurocytoxicity of new marine anticancer agents evaluated using in vitro assays. Cancer Chemother Pharmacol. 44:1999;312-318.
50. Demetri G., Garcia-Carbonero R., Harmon D., Seiden M., Jimeno J., Merriam P., Waxman A., Supko J., Quigley M.T., Ryan D. Ecteinascidin-743 (ET-743) induces objective responses and disease control in patients with advanced non-osseous sarcomas: results from phase II trials. Ann Oncol. 11:(Suppl 4):2000;126.
51. Le Cesne A., Judson I., Radford J., Blay J.Y., Van Oosterom A., Rodenhuis S., Lorigan P., Di Paola E.D., Jimeno J., Verweij J. Phase II study of ET-743 in advanced soft-tissue sarcoma (ASTS) in adult: A STBSG-EORTC trial. Ann Oncol. 11:(Suppl 4):2000;126.
52. Erba E., Bergamaschi D., Bassano L., Damia G., Ronzoni S., Faircloth G.T., D'Incalci M. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer. 37:2001;97-105.
53. Damia G., Silvestri S., Carrassa L., Filiberti L., Faircloth G.T., Liberi G., Foiani M., D'Incalci M. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer. 92:2001;583-588.
54. Minuzzo M., Marchini S., Broggini M., Faircloth G., D'Incalci M., Mantovani R. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci USA. 97:2000;6780-6784.
55. Poncet J. The dolastatins, a family of promising antineoplastic agents. Curr Pharm Des. 5:1999;139-162.
56. Bai R., Pettit G.R., Hamel E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol. 39:1990;1941-1949.
57. Pathak S., Multani A.S., Ozen M., Richardson M.A., Newman R.A. Dolastatin 10 induces polyploidy, telomeric associations and apoptosis in a murine melanoma cell line. Oncol Res. 5:1998;373-376.
58. Wright J.J., Blatner G., Cheson B.D. Clinical trials referral resource. Clinical trials of dolastatin 10. Oncology. 13:1999;68-70.
59. Pitot H.C., McElroy E.A., Reid J.M., Windebank A.J., Sloan J.A., Erlichman C., Bagniewski P.G., Walker D.L., Rubin J., Goldberg R.M., et al. Phase I trial of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res. 5:1999;525-531.
60. Madden T., Tran H.T., Beck D., Huie R., Newman R.A., Pusztai L., Wright J.J., Abbruzzese J.L. Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res. 6:2000;1293-12301.
61. Krug L.M., Miller V.A., Kalemkerian G.P., Kraut M.J., Ng K.K., Heelan R.T., Pizzo B.A., Perez W., McClean N., Kris M.G. Phase II study of dolastatin 10 in patients with advanced non-small-cell lung cancer. Ann Oncol. 11:2000;227-228.
62. Pettit G.R. The bryostatins. Fortschr Chem Org Naturst. 57:1991;153-195.
63. Pagliaro L., Daliani D., Amato R., Tu S.M., Jones D., Smith T., Logothetis C., Millikan R.A. Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer. 89:2000;615-618.
64. Zonder J.A., Shields A.F., Zalupski M., Chaplen R., Heilbrun L.K., Arlauskas P., Philip P.A. A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer. Clin Cancer Res. 7:2001;38-42.
65. Propper D.J., Macaulay V., Obyrne K.J., Braybrooke J.P., Wilner S.M., Ganesan T.S., Talbot D.C., Harris A.L. A phase II study of bryostatin 1 in metastatic malignant melanoma. Br J Cancer. 78:1998;1337-1341.
66. Varterasian M.L., Mohammad R.M., Shurafa M.S., Hulburd K., Pemberton P.A., Rodriguez D.H., Spadoni V., Eilender D.S., Murgo A., Wall N., et al. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin Cancer Res. 6:2000;825-828.
67. Ahmad I., Al-Katib A.M., Beck F.W., Mohammad R.M. Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenoside: case report. Clin Cancer Res. 6:2000;1328-1332.